NEAAV
Live / Applied — Fourth extension granted (statement of use) (as of 01 Jul 2025)
What this means for you
Not registered yet, but its 12 Jun 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97454586
- Mark type
- Stylized text
- Filed
- 12 Jun 2022
- Published for opposition
- 30 May 2023
- Attorney of record
- Kristen Mollnow Walsh
Goods and services
- Class 001 — Chemicals: Chemical preparations, enzymes, DNA vectors, and DNA extracts for the preparation of nucleic acid for scientific and research purposes; chemicals for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; enzymes for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; DNA extracts and cassettes for scientific and research use; DNA extracts for scientific and research purposes in the fields of agri-biotechnology and nanotechnology; Biological and biochemical reagents being RNA polymerase, DNA polymerase, DNA plasmid vectors, DNA vectors, rAAV vectors, and RNA markers that form a gene analysis system not for medical purposes; Diagnostic reagents for scientific or research purposes, namely, a diagnostic kit consisting primarily of DNA plasmid vectors
- Class 005 — Pharmaceuticals: Vaccines; DNA based vaccines; DNA extracts, namely, nucleic acid sequences and chemical reagents for medical use; Therapeutic DNA, namely, nucleic acid sequences and chemical reagents for medical and veterinary purposes; Biotechnological product, namely, viral DNA vectors, for the delivery of genes and other materials in the nature of RNA and transcriptional targeting promoters, to a biological cell for medical purposes; biological preparations, namely, DNA extracts for production of viral vectors for medical purposes
- Class 042 — Scientific and technological services: Scientific and technological services, namely, research and design in the field of DNA research and development; chemical and biological analysis and research services; scientific research in the field of DNA; scientific research and development in the field of creating DNA extracts; scientific and technological services, namely, scientific research, analysis, design and development in the field of DNA based pharmaceutical drugs and therapies; scientific research and development in the fields of gene therapy, diagnostics, agri-biotechnology and nanotechnology; scientific consultancy services in the fields of gene therapy, diagnostics, agri-biotechnology, nano technology, and DNA analysis
Owner
- Asklepios BioPharmaceutical, Inc., Research Triangle Park, NC, US
- Asklepios BioPharmaceutical, Inc., Research Triangle Park, NC, US
Prosecution history
- 13 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 02 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Jul 2025 — SOU EXTENSION 4 GRANTED
- 01 Jul 2025 — SOU EXTENSION 4 FILED
- 01 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Jan 2025 — SOU EXTENSION 3 GRANTED
- 07 Jan 2025 — SOU EXTENSION 3 FILED
- 07 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 24 Jul 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Jul 2024 — SOU EXTENSION 2 GRANTED
- 24 Jul 2024 — SOU EXTENSION 2 FILED
- 24 Jul 2024 — SOU TEAS EXTENSION RECEIVED
- 08 May 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 08 May 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED